Millennium Management’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-921,330
| Closed | -$21.8M | – | 6801 |
|
|
2023
Q4 | $21.8M | Buy |
921,330
+777,926
| +542% | +$13.9M | 0.01% | 1474 |
|
|
2023
Q3 | $2.14M | Sell |
143,404
-1,300,590
| -90% | -$17.2M | ﹤0.01% | 3496 |
|
|
2023
Q2 | $15.8M | Sell |
1,443,994
-1,505,062
| -51% | -$14M | 0.01% | 1607 |
|
|
2023
Q1 | $25.7M | Buy |
2,949,056
+2,018,868
| +217% | +$16.2M | 0.01% | 1161 |
|
|
2022
Q4 | $5.83M | Sell |
930,188
-603,794
| -39% | -$2.29M | ﹤0.01% | 2675 |
|
|
2022
Q3 | $5.37M | Sell |
1,533,982
-1,481,514
| -49% | -$5.32M | ﹤0.01% | 2832 |
|
|
2022
Q2 | $8.9M | Buy |
3,015,496
+642,796
| +27% | +$1.54M | 0.01% | 2184 |
|
|
2022
Q1 | $7.38M | Buy |
2,372,700
+301,913
| +15% | +$950K | ﹤0.01% | 2503 |
|
|
2021
Q4 | $7M | Buy |
2,070,787
+112,134
| +6% | +$426K | ﹤0.01% | 2548 |
|
|
2021
Q3 | $7.15M | Sell |
1,958,653
-144,159
| -7% | -$568K | ﹤0.01% | 2463 |
|
|
2021
Q2 | $9.17M | Buy |
2,102,812
+49,033
| +2% | +$217K | 0.01% | 2022 |
|
|
2021
Q1 | $9.32M | Buy |
2,053,779
+707,731
| +53% | +$3.81M | 0.01% | 1865 |
|
|
2020
Q4 | $7.73M | Sell |
1,346,048
-336,355
| -20% | -$2.55M | 0.01% | 2031 |
|
|
2020
Q3 | $12.2K | Buy |
1,682,403
+838,446
| +99% | +$4.48M | 0.02% | 1098 |
|
|
2020
Q2 | $2.94M | Sell |
843,957
-713,183
| -46% | -$2.06M | ﹤0.01% | 2227 |
|
|
2020
Q1 | $2.31M | Sell |
1,557,140
-1,436,505
| -48% | -$2.41M | 0.01% | 1918 |
|
|
2019
Q4 | $5.87M | Sell |
2,993,645
-730,152
| -20% | -$2.74M | 0.01% | 1797 |
|
|
2019
Q3 | $19.1M | Buy |
3,723,797
+740,380
| +25% | +$4.48M | 0.03% | 810 |
|
|
2019
Q2 | $21.4M | Buy |
2,983,417
+1,281,717
| +75% | +$14.5M | 0.03% | 744 |
|
|
2019
Q1 | $22.6M | Buy |
1,701,700
+538,548
| +46% | +$5.73M | 0.03% | 737 |
|
|
2018
Q4 | $9.15M | Buy |
1,163,152
+253,377
| +28% | +$2.41M | 0.01% | 1186 |
|
|
2018
Q3 | $10.1M | Sell |
909,775
-258,857
| -22% | -$3.22M | 0.01% | 1315 |
|
|
2018
Q2 | $15.7M | Buy |
1,168,632
+8,357
| +0.7% | +$105K | 0.02% | 1019 |
|
|
2018
Q1 | $15.1M | Buy |
1,160,275
+1,094,594
| +1,667% | +$13.6M | 0.02% | 1063 |
|
|
2017
Q4 | $604K | Sell |
65,681
-1,637,443
| -96% | -$14M | ﹤0.01% | 2999 |
|
|
2017
Q3 | $13.7M | Buy |
1,703,124
+1,277,226
| +300% | +$8.64M | 0.02% | 1028 |
|
|
2017
Q2 | $2.45M | Buy |
425,898
+387,783
| +1,017% | +$1.65M | ﹤0.01% | 1962 |
|
|
2017
Q1 | $164K | Buy |
+38,115
| New | +$109K | ﹤0.01% | 3256 |
|
Other funds holding CBAY
Millennium Management's CBAY Position: Q1 2024 in Review
Millennium Management sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 921,330 shares — an estimated $21.8M sold.
Millennium Management first reported a position in CBAY in Q1 2017 and held it in 28 quarters. The position peaked at $25.7M in Q1 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Millennium Management reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Millennium Management sold 921,330 Cymabay Therapeutics shares in Q1 2024, an estimated $21.8M.
- Millennium Management first reported a position in Cymabay Therapeutics in Q1 2017 and held it in 28 quarters.
- Millennium Management's Cymabay Therapeutics position peaked at $25.7M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Millennium Management's 13F filing for Q1 2024, filed 15 May 2024.